Alembic Pharmaceuticals Ltd (APLLTD) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Alembic Pharmaceuticals reported strong Q4 FY25 results with a 17% revenue growth, reaching Rs. 1,770 crores.
- EBITDA for the quarter stood at Rs. 286 crores, representing a 9% growth.
- For the full FY25, revenue grew by 7% to Rs. 6,672 crores, and EBITDA increased by 10% to Rs. 1,053 crores.
- The company's International business, particularly the ex-US segment, performed exceptionally well, achieving a 43% growth in Q4.
- The board announced a dividend of Rs. 11 per share (550%) for FY25, subject to shareholder approval.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.